Development of Inhibitors Against HCV Infection

Information

  • Research Project
  • 6482700
  • ApplicationId
    6482700
  • Core Project Number
    R43AI049592
  • Full Project Number
    1R43AI049592-01A1
  • Serial Number
    49592
  • FOA Number
  • Sub Project Id
  • Project Start Date
    6/1/2002 - 22 years ago
  • Project End Date
    6/30/2003 - 21 years ago
  • Program Officer Name
    PODSKALNY, JUDITH M.
  • Budget Start Date
    6/1/2002 - 22 years ago
  • Budget End Date
    6/30/2003 - 21 years ago
  • Fiscal Year
    2002
  • Support Year
    1
  • Suffix
    A1
  • Award Notice Date
    5/31/2002 - 22 years ago
Organizations

Development of Inhibitors Against HCV Infection

DESCRIPTION (Provided by applicant): Hepatitis C viral infection is the most common chronic bloodborne infection in the United States. There are about 36,000 new infections every year, and 25-30 percent of those infections are symptomatic. It is estimated that 3.9 million (1.8 percent) Americans have been infected. Chronic liver disease, which is caused by HCV infection, is the tenth leading cause of death among adults in the United States, accounting for approximately 1 percent of all deaths. To date, there is no efficient culture system available to evaluate the activity of compounds against HCV in vitro. To overcome this difficulty, surrogate animal viruses are being used, including bovine viral diarrhea virus, yellow fever virus, dengue virus, and banzi virus. We have identified a compound (ZX-2401) that shows a significant antiviral activity against these surrogate viruses. The overall scope of this application is to investigate the feasibility of this compound and its derivatives as potential inhibitors of HCV. The specific aims for these novel compounds include synthesizing ZX-2401 or derivatives as needed for the proposed studies, performing in vitro antiviral studies in HCV replicon system and cytotoxicity testing, performing studies in combination with IFN-alpha, and performing mechanism of action studies.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R43
  • Administering IC
    AI
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    100000
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    856
  • Ed Inst. Type
  • Funding ICs
    NIAID:100000\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    ZYMETX, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    OKLAHOMA CITY
  • Organization State
    OK
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    73104
  • Organization District
    UNITED STATES